Acute heparin-induced thrombocytopenia type II during pregnancy - An interdisciplinary challenge;Die akute heparininduzierte thrombozytopenie typ II während der schwangerschaft - Eine interdisziplinäre herausforderung

Intensivmedizin und Notfallmedizin

Volumn 43, Issue 1, 2006, Pages 12-28

  Schinzel, H ^a   Peetz, D ^b   Wiechelt, J ^a   Von Mach, M A ^a   Macciella, D ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Alternative anticoagulation; Danaparoid sodium; Heparin induced thrombocytopenia type II; Pregnancy

Indexed keywords

COUMARIN; DANAPAROID; HEPARIN; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN;

CARDIOVASCULAR RISK; CLINICAL TRIAL; DIAGNOSTIC TEST; HEMOPERITONEUM; HUMAN; PATHOPHYSIOLOGY; PREGNANCY; REVIEW; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 32944456110     PISSN: 01753851     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00390-006-0639-8     Document Type: Review

References (111)

1. Aijaz A, Nelson J, Nasser N (2001) Management of heparin allergy in pregnancy. Am J Hematology 67:268-269
2. Amiral J, Bridey F, Wolf M et al (1995) Antibodies to macromoelecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia. Thromb Haemost 73:21-28
3. Barbour LA (1997) Current concepts of anticoagulant therapy in pregnancy. Obstet Gynecol Clin North Am 24(3):499-521
4. Bergqvist D, Hedner U, Sjorin E, Holmer E (1983) Anticoagulant effects of two types of low molekular weight heparin administered subcutaneoulsy. Thomb Res 32:381-391
5. Blombäck M (1991) Changes in blood coagulation and fibrinolysis during pregnancy and the menstrual cycle: new methods for dedecting the changes. Advances in Contraception (Suppl 3)7:259-272
6. Boshkov LK, Hamilton P, Lee A, Boldt K (1999) Successful therapy of heparin-induced thrombocytopenia with thrombosis (HITTS) in pregnancy with danaparoid sodium (Orgaran). Blood 94 Suppl 1. Ref Type Abstract
7. Bove CM, Casey B, Marder VJ (1996) DDAVP reduces bleeding during continued hirudin administration in the rabbit. Thromb Haemost 75:471-475
8. Bradbrook ID, Magnani HN, Moelker HC, Morrison PJ, Robinson J, Rogers HJ et al (1987) ORG 10172: a low molecular weight heparinoid anticoagulant with a long half-life in man. Br J Clin Pharmacol 23(6):667-675
9. Bucha E, Nowak G, Czerwinski R, Thieler H (1999) R-hirudin as anticoagulant in regular hemodialysis therapy: finding of therapeutic R-hirudin blood/plasma concentrations and respective dosages. Clin Appl Thromb Hemost 5(3):164-170
10. Butler KD, Dolan SL, Talbot MD, Wallis RB (1993) Factor VII and DDAVP reverse the effect of recombinant desulphatohirudin (CGP 39393) on bleeding in the rat. Blood Coagul Fibrinolysis 4:459-464
11. Chong BH, Castaldi PA (1986) Heparin-induced thrombocytopenia: further studies of the effects of heparin-dependent antibodies on platelets. Br J Haematol 64:347-354
12. Danhof M, de Boer A, Magnani HN, Stiekema JC (1992) Pharmacokinetic considerations on Orgaran (Org 10172) therapy. Haemostasis 22(2): 73-84
13. Demers C, Ginsberg JS, Brill-Edwards P, Panju A, Warkentin TE, Anderson DR et al (1991) Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia. Blood 78(9):2194-2197
14. Dempfle CE (2004) Minor transplecental passage of fondaparinux in vivo. N Engl J Med 350:1914-1915
15. Department of Health (1994) Report in confidential enquiries into maternal death in the United Kingdom 1988-1990. HMSO, London
16. Deschamps A, Mathelier-Fusade P, Bernaille J (2004) Reaction cutanee a l'heparine pendant la grossesse: a propos d'un cas traite avec succes par le danaparoide. Rev Francaise Allergol. Immunol Clin 43:131-134
17. de Swiet M, Dorrington-Ward P, Fidler J, Horsman A, Katz D, Letzky E, Peacock M, Wise PH (1983) Prolonged heparin therapy in pregnancy cause bone demineralisation. Brit J Obstet Gynaecol, pp 1129-1134
18. Eichler P, Friesen HJ, Lubenow N, Jaeger B, Greinacher A (2000) Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood 96(7):2373-2378
19. Erikkson BI, Ekman S, Lindbratt S et al (1997) Prevention of thromboembolism with use of recombinant hirudin: results of a double-blind, multicenter trial comparing the efficancy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. J Bone Joint Surg Am 79:326-333
20. Erikkson BI, Wille-Jörgensen P, Kälebo P et al (1997) A comparison of recombinant hirudin with low-molecular weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 337: 1329-1335
21. Fischer KG (2002) Hirudin in renal insufficiency. Semin Thromb Hemost 28:467-482
22. Fontana P (2004) Skin necrosis is a clinical manifestation of low-molecular weight heparin-induced thrombocytopenia. A case report. Thromb Haemost 91:196-197
23. Frei U, Wilks MF, Boehmer S, Crisp-Lindgren N, Schwarzrock R, Stiekema JC et al (1988) Gastrointestinal blood loss in haemodialysis patients during use of a low-molecular-weight heparinoid anticoagulant. Nephrol Dial Transplant 3(4):435-439
24. Gerhardt A, Zotz RB, Scheja JW (2000) First successful use of danaparoid in a pregnant woman with tricuspidal valve prothesis and heparin-induced thrombocytopenia in pregnancy with subcutaneous r-hirudin. Blood 96:95 b
25. Gill J, Kovacs MJ (1997) Successful use of danaparoid in treatment of heparin-induced thrombocytopenia during twin pregnancy. Obstet Gynecol 90(4 Pt 2):648-650
26. Gould J, Meyers B (2002) Prophylactic danaparoid in heparin-induced thrombocytopenia presenting with skin manifestations in pregnancy. Blood Coagul Fibrinolysis, p 13. Ref Typ: Abstract
27. Ginsberg JS, Hirsh J (1989) Anticoagulation during pregnancy. Am Rev Med 40:79-86
28. Ginsberg JS, Kowalchuk G, Hirsh J, Brill-Edwards P, Burrows R, Coates G, Webber C (1990) Heparin effect on bone density. Thromb and Haemost 64:286-289
29. Ginsberg JS, Greer I, Hirsh J (2001) Use of antithrombotic agents during pregnancy. Chest 119(1 Suppl):122-131
30. Grainger JD, Hay C (2001) Heparin induced thrombocytopenia caused by danaparoid sodium. Thromb Haemost Abstract CD3458 presented at IVIII ISTH. Ref Type: Abstract
31. Greinacher A, Michels I, Kiefel V, Mueller-Eckhardt C (1991) A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost 66:734-736
32. Greinacher A, Michels I, Mueller-Eckhardt C (1992) Heparin-associated thrombocytoepnia: the antibody is not heparin specific. Thromb Haemost 67:545-549
33. Greinacher A, Eckhardt T, Mussmann J, Mueller-Eckhardt C (1993) Pregnancy complicated by heparin associated thrombocytopenia: management by a prospectively in vitro selected heparinoid (Org 10172). Thromb Res 71(2):123-126
34. Greinacher A (1999) Heparin-induzierte Thrombozytopenie - Pathogenese und Behandlung. Haemostaseologie, S 19:1-12
35. Greinacher A, Volpel H, Janssens U, Hach-Wunderle V, Kemkes-Matthes B, Eichler P et al (1999) Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 99(1):73-80
36. Greinacher A, Janssens U, Berg G, Bock M, Kwasny H, Kemkes-Matthes B et al (1999) Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators. Circulation 100(6):587-593
37. Greinacher A, Lubenow N, Hinz P, Ekkernkamp A (2003) Heparininduzierte Thrombozytopenie. Deutsches Ärzteblatt 100(34-35):1753-1759
38. Greinacher A, Warkentin TE (2003) Treatment of heparin-induced thrombocytopenia: an overview In: Warkentin TE, Greinacher A (eds) Heparin-induced thrombocytopenia. Marcel Dekker, New York, pp 335-370
39. Griffith GC, Nichols G, Asher JD, Flanagan B (1965) Heparin osteoporosis. J Am Med Ass 193:85-88
40. Hall JG, Pauli RM, Wilson KM (1980) Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 68 (1):122-140
41. Hamilton P (1999) ABC of labour care: care of the newborn in the delivery room. BMJ 318(7195):1403-1406
42. Harenberg J, Leber G, Zimmermann R, Schmidt W (1987) Thromboembolieprophylaxe mit niedermolekularem Heparin in der Schwangerschaft. Geburtshilfe Frauenheilkunde 47:15-18
43. Harenberg J, Schneider D, Heilmann L, Wolf H (1993) Lack of anti-Xa activity in umbilical cord vein samples after subcutaneous administration of heparin or low molecular weight heparin in pregnant women. Haemostasis 47:314-320
44. Harrison SJ, Rafferty I, McColl MD (2001) Management of heparin allergy during pregnancy with danaparoid. Blood Coagul Fibrinolysis 12(2):157-159
45. Henny CP, ten Cate H, ten Cate JW, Prummel MF, Peters M, Buller HR (1980) Thrombosis prophylaxis in an AT III deficient pregnant woman: application of a low molecular weight heparinoid. Thromb Haemost 1986; 55(2):301;
46. Am J Med 68(1):122-140
47. Herault JP, Bernat A, Pflieger A (1997) Comparative effect of two direct and indirect inhibitors on free and clot-bound prothrombinase. J Pharmacol Exp Ther 283:16-22
48. Horellou M, Elalamy I, Achkar A (2001) Efficacy and safety of danaparoid (Orgaran) in venous thrombosis in pregenant women with thrombophilia and heparin-induced thrombocytopenia. Thromb.Haemost. Suppl Abstract of the XVIII ISTH. Ref Type: Abstract
49. Huhle G, Geberth M, Hoffmann U, Heene DL, Harenberg J (2000) Management of heparin-associated thrombocytopenia in pregnancy with subcutaneous r-hirudin. Gynecol Obstet Invest 49(1):67-69
50. Iturbe-Alessio I, Fonseca MC, Mutchinik O, Santos MA, Zajarias A, Salazar E (1986) Risks of anticoagulant therapy in pregnant women with artificial heart valves. N Engl J Med 315(22):1390-1393
51. Johnson EA, Kirkwood TBL, Stirling Y, Perez-Requejo IL, Ingram GIC, Bangham DR, Brozovic M (1976) Four heparin preparations. Anti-Xa potentiating effect of heparin after subcutaneous injection. Thromb and Haemost 38:586-591
52. Kapch D, Silver D (1981) Heparin-induced thrombocytopenia, thrombosis and haemorrhage. Arch Surg 116: 1423-1429
53. Kemkes-Matthes B (1999) Heparin-induzierte Thrombozytopenie. UNIMED Verlag, Bremen
54. Lagrange F, Brun JL, Vergnes MC, Paolucci F, Nadal T, Leng JJ, Saux MC, Bannwarth B (2002) Fondaparinux sodium does not cross the placental barrier: study using the in-vitro human dually perfused cotyledon model. Clin Pharmacokinet 41(Suppl 2):47-49
55. Lanska DJ, Kryscio RJ (2000) Risk factors for peripartum and postpartum stroke and intracranial venous thrombosis. Stroke 31(6):1274-1282
56. Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM et al (2001) Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 103(14):1838-1843
57. rd ed. New York: Marcel Dekker, pp 437-474
58. Liebe V, Bruckmann M, Fischer KG, Haase KK, Borggrefe M, Huhle G (2002) Biological relevance of anti-recombinant hirudin antibodies - results from in vitro and in vivo studies. Semin Thromb Hemost 28(5):483-490
59. Lincoff AM, Bittl JA, Kleimann NS, Sarembock IJ, Jackman JD, Mehta S, Tannenbaum MA, Niederman AL, Bachinsky WB, Tiftmann J, Parker HG, Kereiakes DJ, Harrington RA, Feit F, Maierson ES, Chew DP, Topol EJ (2004) REPLACE-1 Inverstigators. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the randomized evaluation of PCI linking Angiomax to reduced clinical events (REPLACE)-1 trial). Am J Cardiol 93:1092-1096
60. Lindhoff-Last E, Willeke A, Thalhammer C, Nowak G, Bauersachs R (2000) Hirudin treatment in a breast-feeding woman. Lancet 355:467-468
61. Lindhoff-Last E, Bauersachs R (2002) Heparin-induced thrombocytopenia- alternative anticoagulation in pregnancy and lactation. Semin Thromb Hemost 28(5):439-446
62. Lindhoff-Last E, Kreutzenbeck HJ, Magnani HN (2005) Treatment of 51 pregnancies with danaparoid because of heparin intolerance. Thromb Haemost 93:63-69
63. Lubenow N, Kempf R, Eichner A, Eichler P, Carlsson LE, Greinacher A (2002) Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest 122(1):37-42
64. Macchi L, Sarfati R, Guicheteau M, Chamlian V, Pourrat O, Gruel Y et al (2000) Thromboembolic prophylaxis with danaparoid (Orgaran) in a high-thrombosis-risk pregnant woman with a history of heparin-induced thrombocytopenia (HIT) and Widal's disease. Clin Appl Thromb Hemost 6(4):187-189
65. Macklon NS, Greer IA (1996) Venous thromboembolic disease in obstetrics and gynaecology: the Scottish experience. Scott Med J 41(3):83-86
66. Magnani HN (1993) Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost 70(4):554-561
67. Magnani HN (1997) Orgaran (danaparoid sodium) use in the syndrome of heprain-induced thrombocytopenia. Platelets 8:74-81
68. Markwardt F (1956) Untersuchungen über den Mechanismus der blutgerin-nungshemmenden Wirkung des Hirudins. N-S Arch Phamacol 229:389-399
69. Markwardt F (1992) Hirudin: The promising antithrombotic. Cardiovasculary Drug Review 10:211-232
70. McColl MD, Ramsay JE, Tait RC, Walker ID, McCall F, Conkie JA et al (1997) Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 78(4):1183-1188
71. McColl MD, Walker ID, Greer IA (1999) The role of inherited thrombophilia in venous thromboembolism associated with pregnancy. Br J Obstet Gynaecol 106(8):756-766
72. McColl MD, Ellison J, Reid F, Tait RC, Walker ID, Greer IA (2000) Prothrombin 20210 G→A, MTHFR C677T mutations in women with venous thromboembolism associated with pregnancy. BJOG 107(4):565-569
73. Meuleman DG (1992) Orgaran (Org 10172): its pharmacological profile in experimental models. Haemostasis 22(2):58-65
74. Nowak G, Bucha E, Goock T, Thieler H, Markwardt F (1992) Pharmacology of r-hirudin in renal impairment. Thromb Res 66(6):707-715
75. Nowak G, Bucha E (1996) Quantitative determination of hirudin in blood and body fluids. Semin Thromb Hemost 22(2):197-202
76. Ofosu FA (1992) Anticoagulant mechanisms of Orgaran (Org 10172) and its fraction with high affinity to antithrombin III (Org 10849). Haemostasis 22(2):66-72
77. Ortel TL, Chong BH (1998) New treatment options for heparin-induced thrombocytopenia. Semin Hematol 35(4Suppl5):26-34.17
78. Peeters LL, Hobbelen PM, Verkeste CM, Vogel GM, Hasenack HG, Meuleman DG et al (1986) Placental transfer of Org 10172, a low-molecular weight heparinoid, in the awake late-pregnant guinea pig. Thromb Res 44(3):277-283
79. Poetzsch B, Madlener K, Seelig C, Riess CF, Greinacher A, Muller-Berghaus G (1997) Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass-assessment of the whole blood ecarin clotting time. Thromb Haemost 77(5):920-925
80. Pohl C, Klockgether T, Greinacher A, Hanfland P, Harbrecht U (1999) Neurological complications in heparin-induced thrombocytopenia. Lancet 353(9165):1678-1679
81. Rondeau M, Weber JC, Haffner C (2000) HELLP syndrome, catastrophic antipholspholipid syndrome or heparin-induced thrombocytopenia? J Autoimmun 15:A68
82. Sachs BP, Brown DA, Driscoll SG, Schulman E, Acker D, Ransil BJ et al (1987) Maternal mortality in Massachusetts. Trends and prevention. N Engl J Med 316(11):667-672
83. Saint-Blanquat L, Simon L, Toubas MF, Hamza J (2000) [Treatment with danaparoid during pregnancy for a woman with a cutenous allergy to low-molecular-weight heparin]. Ann Fr Anesth Reanim 19(10):751-754
84. Schinzel H, Bahlmann F, Peetz D, Savvidis S, Himmrich L, Klotz M (2002) [Prevention of thromboembolism with low molecular weight heparin (Dalteparin-Na) in risk pregnancy]. Med Klin 97(4):193-203
85. Schinzel H (2004) Klinische Erfahrungen mit der intravenösen Applikation von niedermolekularen Heparinen. VascCare 2:22-31
86. Schindelwolf M, Mosch G, Bauersachs RM et al (2004) Safe anticoagulation with danaparoid in pregancy and lactation Thromb Haemost 92(1):211
87. Schmahl KS, Ganjoo AK, Harloff MG (1996) Orgaran (Org 10172) for cardiopulmonary bypass in heparin-induced thrombocytopenia: role of adjunctive plasmapheresis. J Cardiothorac Vasc Anesth 10:521-530
88. Sheridan D, Carter C, Kelton JG (1986) A diagnostic test for heparin-induced thrombocytopenia. Blood 67/ 1:27-30
89. Stiekema JC, Wijnand HP, Van Dinther TG, Moelker HC, Dawes J, Vinchenzo A et al (1989) Safety and pharmacokinetics of the low molecular weight heparinoid Org 10172 administered to healthy elderly volunteers. Br J Clin Pharmacol 27(1):39-48
90. Stiekema JC, Wijnand HP, ten Cate H, ten Cate JW, Harenberg J, Egberts JF et al (1991) Partial in vivo neutralisation of plasma anticoagulant effects of Lomoparan (Org 10172) by protamine chloride. Thromb Res 63(1):157-167
91. Stiekema JC, Van Griensven JM, Van Dinther TG, Cohen AF (1993) A cross-over comparison of the anticlotting effects of three low molecular weight heparins and glycosaminoglycuronan. Br J Clin Phamacol 36: 51-56
92. Stratmann G, deSilva AM, Tseng EE, Hambleton J, Balea M, Romo AJ, Mann MJ, Achorn NL, Moskalik WF, Hoopes CW (2004) Reversal of direct thrombin inhibitor after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. Anesth Analg 98:1635-1639
93. Taylor AA (2001) Successful use of heparinoids in a pregnancy complicated by allergy to heparin. BJOG 108(9):1011-1012
94. Toglia MR, Weg JG (1996) Venous thromboembolism during pregnancy. N Engl J Med 335(2):108-114
95. van Besien K, Hoffman R, Golichowski A (1991) Pregnancy associated with lupus anticoagulant and heparin induced thrombocytopenia: management with a low molecular weight heparinoid. Thromb Res 62(1-2):23-29
96. Vanholder RC, Camez AA, Veys NM, Soria J, Mirshahi M, Soria C et al (1994) Recombinant hirudin: a specific thrombin inhibiting anticoagulant for hemodialysis. Kidney Int 45(6):1754-1759
97. Vanholder R, Camez A, Veys N, Van Loo A, Dhondt AM, Ringoir S (1997) Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients. Thromb Haemost 77(4):650-655
98. Van Wersch JW, Ubachs JM (1991) Blood coagulation and fibrinolysis during normal pregnancy. Eur J Clin Chem Clin Biochem 29(1):45-50
99. von Felten A (1992) Venöse Thromboembolieprophylaxe mit Heparin bei Risikopatientinnen während der Schwangerschaft: Monitorisierung mittels Messung der Thrombin-Antithrombin-III-Komplexe. Therapeutische Umschau 49:838-841
100. von Hugo R, Theiss W, Kuhn W, Graeff H (1984) [Thromboembolism in obstetrics]. Gynäkologe 17(2):115-123
101. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M et al (1995) Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332(20):1330-1335
102. Warkentin TE, Kelton JA (1996) A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996; 101:5027
103. Warkentin TE (1996) Danaparoid (Orgaran) for the treatment of heparin-induced thrombocytopenia (HIT) and thrombosis: Effects on in vivo thrombin and cross-linked fibrin generation, and evaluation of the clinical significance of in vitro cross-reactivity (XR) of danaparoid for HIT-IgG. Blood 88:626 A. Ref Type: Abstract
104. Warkentin TE (1997) Heparin-induced thrombocytopenia. Pathogenesis, frequency, avoidance and management. Drug Safty 17:325-341
105. Warkentin TE, Chong BH, Greinacher A (1998) Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 79(1):1-7
106. Warkentin TE (2001) Clinical picture of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A (eds) Heparin-induced thrombocytopenia, 2nd edn. Marcel Dekker, New York, pp 43-86
107. Warkentin TE, Kelton JG (2001) Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 344(17):1286-1292
108. Warkentin TE, Greinacher A (2001) Laboratory testing for heparin-induced thrombocytoepenia. In: Warkentin TE, Greinacher A (eds) Heparin-induced thrombocytopenia, 2nd edn. Marcel Dekker, New York, pp 231-270
109. Greinacher A, Warkentin TE (2001) Treatment of heparin-induced thrombocytopenia: An overview. In: Warkentin TE, Greinacher A (eds) Heparin-induced thrombocytopenia, 2nd edn. Marcel Dekker, New York, pp 291-322
110. Wong V, Cheng CH, Chan KC (1993) Fetal and neonatal outcome of exposure to anticoagulants during pregnancy. Am J Med Genet 45(1):17-21
111. Woo YL, Allard S, Cohen H, Letsky E, de Swiet M (2002) Danaparoid thromboprophylaxis in pregnant women with heparin-induced thrombocytopenia. BJOG 109(4):466-468 Hersteller